Efficacy of Erenumab in the Treatment of Trigeminal Neuralgia: A Retrospective Case Series

Eliot Parascandolo, Kelsey Levinson, Paul Rizzoli, Roni Sharon*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

ObjectiveTrigeminal neuralgia (TN) is a chronic, often refractory, pain condition, which adversely affects the lives of patients. Current treatments are only mildly effective. Anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies have been successfully studied in the treatment of migraines. CGRP plays a role in both TN and migraine. It is prudent to attempt CGRP monoclonal antibody therapy in TN. Erenumab, a human anti-CGRP monoclonal antibody medication, modulates CGRP, which is elevated in patients with TN. The primary objective of this study was to evaluate the efficacy of erenumab for patients with TN.MethodsRetrospective analysis was performed on data collected from 10 patients diagnosed with TN and treated with erenumab for 6 months. Pain was tracked using a numeric pain rating scale (NPRS) from 0 to 10. The effect of erenumab on NPRS after 6 months' time was the primary end point. Secondary end points included side effects to therapy, improvement in headache frequency in those with comorbid migraine, evaluating mood following therapy, and global mood improvement using scale (worse, no change, improved).ResultsNine of 10 patients (90.0%) reported improvement in pain severity and in global mood improvement. Three patients reported resolution of anxiety and/or depression. Side effects were minimal, with 3 patients reporting constipation, injection site reactions, or both.ConclusionsBased on these results, erenumab appears to be an efficacious treatment option for patients with refractory TN. Patients experienced improvement in pain, reduced frequency of headache, and improvement in mood. Treatment was well tolerated with only mild side effects reported.Classification of EvidenceThis study provides Class IV evidence that erenumab increases the probability of improved pain control in patients with medication-resistant TN.

Original languageEnglish
Pages (from-to)227-231
Number of pages5
JournalNeurology: Clinical Practice
Volume11
Issue number3
DOIs
StatePublished - 1 Jun 2021

Fingerprint

Dive into the research topics of 'Efficacy of Erenumab in the Treatment of Trigeminal Neuralgia: A Retrospective Case Series'. Together they form a unique fingerprint.

Cite this